{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:12:00Z","timestamp":1769749920579,"version":"3.49.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000051","name":"U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute","doi-asserted-by":"publisher","award":["5T32HG009495"],"award-info":[{"award-number":["5T32HG009495"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guerry Career Development Award"},{"name":"Colton Center Pilot Award, the Laffey-McHugh Foundation, and the Berman and Maguire Funds for Lymphoma Research at Penn"},{"name":"Scholar in Clinical Research Award from the Leukemia & Lymphoma Society"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01408-4","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:51:08Z","timestamp":1762314668000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of relapse after teclistamab therapy in multiple myeloma"],"prefix":"10.1038","volume":"15","author":[{"given":"Kyle L.","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7937-1557","authenticated-orcid":false,"given":"Matthew","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Paruzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3401-1309","authenticated-orcid":false,"given":"Federico","family":"Stella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heta","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zainul S.","family":"Hasanali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivani","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Waxman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-2566","authenticated-orcid":false,"given":"Dan T.","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward A.","family":"Stadtmauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Fraietta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-5811","authenticated-orcid":false,"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-3843","authenticated-orcid":false,"given":"Adam D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2791-5748","authenticated-orcid":false,"given":"Alfred L.","family":"Garfall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-2518","authenticated-orcid":false,"given":"Sandra","family":"Susanibar-Adaniya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"1408_CR1","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s41375-021-01433-9","volume":"36","author":"S Zanwar","year":"2022","unstructured":"Zanwar S, Ho M, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, et al. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. Leukemia. 2022;36:873\u20136.","journal-title":"Leukemia"},{"key":"1408_CR2","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41375-021-01471-3","volume":"36","author":"S Bal","year":"2022","unstructured":"Bal S, Malek E, Kansagra A, Usmani SZ, Vij R, Godby KN, et al. Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. Leukemia. 2022;36:877\u201380.","journal-title":"Leukemia"},{"key":"1408_CR3","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e46.","journal-title":"Lancet Oncol"},{"key":"1408_CR4","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, Corre J, D\u2019Agostino M, Kaiser MF, et al. International Myeloma Society\/International Myeloma Working Group Consensus recommendations on the definition of high-risk multiple myeloma. J Clin Oncol. 2025;43:2739\u20132751.","journal-title":"J Clin Oncol"},{"key":"1408_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01259-z","volume":"15","author":"CR Tan","year":"2025","unstructured":"Tan CR, Asoori S, Huang C-Y, Brunaldi L, Popat R, Kastritis E, et al. Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study. Blood Cancer J. 2025;15:53.","journal-title":"Blood Cancer J"},{"key":"1408_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","volume":"38","author":"C Riedhammer","year":"2024","unstructured":"Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A, et al. Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia. 2024;38:365\u201371.","journal-title":"Leukemia"},{"key":"1408_CR7","doi-asserted-by":"publisher","unstructured":"Razzo BM, Midha S, Portuguese AJ, Grajales-Cruz AF, De Menezes Silva Corraes A, Costello P, et al. Real-world experience with teclistamab for relapsed\/ refractory multiple myeloma from the U.S. Myeloma Immunotherapy Consortium. Blood Cancer Discov. 2025. https:\/\/doi.org\/10.1158\/2643-3230.BCD-24-0354.","DOI":"10.1158\/2643-3230.BCD-24-0354"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01408-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01408-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01408-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:51:08Z","timestamp":1762314668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01408-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":7,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1408"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01408-4","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.T.V. has received research funding from Takeda and Active Biotech and consulting fees from Takeda, Karyopharm, GSK, Genentech, and Sanofi. E.A.S. declares research funding from AbbVie and K36; consultancy for Amgen, BMS, Celgene, and Janssen. M.R. has patents related to CD19 CAR T-cells; consults for GLG, Guidepoint, AbClon, Acera, Vittoria Bio; research funding received from AbClon, Oxford NanoImaging, Vittoria Biotherapeutics, CURIOX, and Beckman Coulter; scientific founder of Vittoria Biotherapeutics. A.D.C. has received research support from Novartis, GSK, Genentech, and Janssen; consulting fees from Janssen, BMS, GSK, Genentech, Legend, Sanofi, Pfizer, AbbVie, Regeneron, Moderna, AstraZeneca, iTeos, Prothena, Kite, Novartis, Ichnos; and has patents related to CAR T cells. A.L.G. declares research support from Johnson & Johnson, Novartis, Tmunity, and CRISPR Therapeutics; consultancies\/honoraria from Johnson & Johnson, Novartis, BMS, Regeneron, AbbVie, AstraZeneca, Smart Immune, and Gracell Bio; and DSMB membership for Janssen. S.S.A. discloses research funding from Johnson & Johnson and consulting from Johnson & Johnson and Sanofi. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"193"}}